NEW YORK (360Dx) – Quanterix said after the close of markets on Wednesday that it has terminated its license agreement with BioMérieux.

The license had covered commercialization of Quanterix's Simoa immunoassay technology for in vitro diagnostic purposes. With its termination, Quanterix regains control of this portion of its intellectual property.

Financial and other terms of the termination agreement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.